1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 5,750 | 6,250 | 18.04. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 06.04. | Eupraxia Pharmaceuticals Inc: Eupraxia Pharmaceuticals warrants to expire April 20 | 1 | Stockwatch | ||
| 01.04. | Cantor Fitzgerald reiterates Eupraxia stock Overweight rating at $19 | 1 | Investing.com | ||
| 23.03. | Eupraxia Pharmaceuticals Boasts $900 Million Peak Sales Potential: Analyst | 1 | Benzinga.com | ||
| EUPRAXIA PHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
| 23.03. | William Blair initiates Eupraxia stock with Outperform rating | 1 | Investing.com | ||
| 23.03. | William Blair startet Coverage für Eupraxia mit "Outperform" | 1 | Investing.com Deutsch | ||
| 17.03. | Eupraxia Pharmaceuticals Inc: Eupraxia posts 24-week data in high-dose Resolve cohort | 1 | Stockwatch | ||
| 17.03. | Stocks in Play: Eupraxia Pharmaceuticals Inc. | - | Baystreet.ca | ||
| 17.03. | H.C. Wainwright cuts Eupraxia Pharmaceuticals price target on higher costs | 2 | Investing.com | ||
| 17.03. | Eupraxia reports symptom improvement in eosinophilic esophagitis trial | 1 | Investing.com | ||
| 17.03. | EUPRAXIA PHARMACEUTICALS INC. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 13.03. | Eupraxia Pharmaceuticals reports Q4 results | 4 | Seeking Alpha | ||
| 13.03. | Eupraxia Pharmaceuticals Inc.: Eupraxia Pharmaceuticals Reports Fourth Quarter 2025 Financial Results | 509 | GlobeNewswire (Europe) | VICTORIA, British Columbia, March 12, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging... ► Artikel lesen | |
| 06.03. | EUPRAXIA PHARMACEUTICALS INC. - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 23.02. | Bloom Burton initiates Eupraxia stock with buy rating on EoE drug | 2 | Investing.com | ||
| 21.02. | Eupraxia Pharmaceuticals Inc: Eupraxia Pharmaceuticals to list 6,428,574 more shares | 1 | Stockwatch | ||
| 21.02. | Eupraxia Pharmaceuticals Inc: Eupraxia Pharmaceuticals closes $63.2M (U.S.) offering | 1 | Stockwatch | ||
| 20.02. | Eupraxia-Aktie legt nach Kapitalerhöhung über 63 Mio. US-Dollar zu | 1 | Investing.com Deutsch | ||
| 20.02. | Eupraxia Pharmaceuticals closes $63.2M public offering | 1 | Investing.com | ||
| 20.02. | Eupraxia Pharmaceuticals Inc.: Eupraxia Pharmaceuticals Announces Closing of US$63.2 Million Public Offering Including Full Exercise of Underwriter Option | 239 | GlobeNewswire (Europe) | VICTORIA, British Columbia, Feb. 20, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging... ► Artikel lesen | |
| 19.02. | Eupraxia Pharmaceuticals Inc: Eupraxia prices $55-million (U.S.) public offering | 1 | Stockwatch |
1 2 3 Weiter >>
49 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| INOVIO PHARMACEUTICALS | 1,013 | -0,20 % | INOVIO Pharmaceuticals, Inc.: INOVIO Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights | Biologics License Application (BLA) for INO-3107 accepted for review under the Accelerated Approval Program as a potential treatment for adults with Recurrent... ► Artikel lesen | |
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,458 | +1,78 % | PacBio Stock Up on New FFPE Workflow Boosting Cancer Sequencing | ||
| ARBUTUS BIOPHARMA | 4,000 | -0,25 % | Arbutus Biopharma Corporation: Arbutus Receives U.S. FDA Fast Track Designation for Imdusiran for the Treatment of Chronic Hepatitis B | Fast Track designation has the potential to facilitate development and accelerate FDA review of imdusiran WARMINSTER, Pa., April 15, 2026 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:... ► Artikel lesen | |
| XOMA ROYALTY | 33,600 | -0,59 % | XOMA Royalty Corporation: XOMA Royalty Reports 2025 Financial Results and Highlights Recent Business Achievements | Portfolio receipts: • Achieved over $50 million of cash receipts, including $33.6 million in royalties and $16.9 million milestones, in full year 2025 • Total receipts increased 9% with royalties... ► Artikel lesen | |
| CARDIFF ONCOLOGY | 1,547 | +0,85 % | Cardiff Oncology presents preclinical data on cancer drug combo | ||
| IMMUNIC | 0,850 | -0,23 % | Immunic's Next-Gen Oral Multiple Sclerosis Drug Poised To Capture Share, Analyst Says | ||
| IOVANCE BIOTHERAPEUTICS | 3,290 | +0,46 % | Iovance Biotherapeutics, Inc.: Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) | ||
| GUARDANT HEALTH | 77,03 | +0,65 % | Piper Sandler reiterates Guardant Health stock rating on ctDNA data | ||
| CYTOKINETICS | 56,00 | -1,20 % | Can Myqorzo Drive Growth for Cytokinetics Amid Competition? | ||
| COHERUS ONCOLOGY | 1,652 | -1,55 % | Coherus Oncology, Inc.: Coherus Oncology Reports Full Year and Fourth Quarter 2025 Financial Results and Provides Business Update | - LOQTORZI net revenue more than doubled to $40.8 million in 2025 from $19.1 million in 2024 - - Reduced secured and convertible debt by 90% from $480 million to $38.8 million over 2024-2025 - - $172.1... ► Artikel lesen | |
| CURIS | 0,500 | -1,96 % | Curis, Inc.: Curis Provides Fourth Quarter 2025 Business Update | Management to host conference call today at 4:30 p.m. ET
LEXINGTON, Mass., March 19, 2026 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused... ► Artikel lesen | |
| FATE THERAPEUTICS | 1,124 | -5,23 % | Fate Therapeutics, Inc.: Fate Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates | Outpatient treatment enabled under FT819-102 autoimmune basket protocol with patients now treated with FT819 off-the-shelf CAR T-cell therapy as same-day hospital discharge Four systemic sclerosis... ► Artikel lesen | |
| ROCKET PHARMACEUTICALS | 3,340 | +0,30 % | Aktien New York: Weitere Verluste - Iran-Krieg und China-News belasten | NEW YORK (dpa-AFX) - Die US-Aktienmärkte haben am Freitag ihre Talfahrt fortgesetzt. Der anhaltende Iran-Krieg und die weiter steigenden Ölpreise mahnen die Anleger zur Vorsicht. Auf die Stimmung drückte... ► Artikel lesen | |
| AGENUS | 3,920 | -3,45 % | Agenus legt gemischte Studiendaten für Krebstherapie-Kombination vor | ||
| VERASTEM | 5,582 | -0,11 % | H.C. Wainwright reiterates Verastem stock rating on durable trial data |
Das Unternehmen EUPRAXIA PHARMACEUTICALS INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell +2,54 % bei einem Aktienkurs von 6,050 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu EUPRAXIA PHARMACEUTICALS INC finden Sie auf Wallstreet Online.